Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic Cancer

BACKGROUND AND PURPOSE: A phase 2 study LAPACT indicated nab-paclitaxel plus gemcitabine (AG) improved outcomes of patients with locally advanced pancreatic cancer (LAPC). Conventional radiotherapy failed to show benefit, indicating high dose to volume with high risk of recurrence is needed. The hig...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Zhan, Yang, Ju, Kong, Weiwei, Qiu, Xin, Lu, Changchang, Liu, Juan, Liu, Baorui, Du, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922029/
https://www.ncbi.nlm.nih.gov/pubmed/35299738
http://dx.doi.org/10.3389/fonc.2022.782730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922029/
https://www.ncbi.nlm.nih.gov/pubmed/35299738
http://dx.doi.org/10.3389/fonc.2022.782730

Ejemplares similares